Companies › Orano Med
1 active drug program in 1 registered trial: 1 Phase 2; Oncology; next expected readout Dec 2030.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| 212Pb-DOTAMTATE (AlphaMedix) Somatostatin receptor 2 (SSTR2)-targeting alpha-emitter therapy; radiolabeled octreotide a | SSTR2 | Phase 2 | Neuroendocrine Tumors | Dec 2030 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05153772 | 212Pb-DOTAMTATE (AlphaMedix) | Phase 2 | Neuroendocrine Tumors | Oncology | Dec 2030 |
ITM Solucin Advanced Accelerator Applications Newish Technology (Beijing) BrainChild Bio TVAX Biomedical
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.